BR0113400A - Método para seleção de peptìdeo - Google Patents
Método para seleção de peptìdeoInfo
- Publication number
- BR0113400A BR0113400A BR0113400-0A BR0113400A BR0113400A BR 0113400 A BR0113400 A BR 0113400A BR 0113400 A BR0113400 A BR 0113400A BR 0113400 A BR0113400 A BR 0113400A
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- selection method
- peptide selection
- selecting
- molecule
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 238000010187 selection method Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003614 tolerogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
Abstract
"MéTODO PARA SELEçãO DE PEPTìDIO". Proporciona-se um método para a seleção de um peptídio tolerogênico, pela seleção de um peptídeo que é capaz de se ligar a uma molécula de MHC de classe I ou II, sem processamento adicional. Proporciona-se também um peptídio selecionado por esse método e o seu uso em uma composição farmacêutica e um método para tratar e/ou prevenir uma doença.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0020618A GB0020618D0 (en) | 2000-08-21 | 2000-08-21 | Peptide selection method |
GB0114547A GB0114547D0 (en) | 2001-06-14 | 2001-06-14 | Peptide selection method |
PCT/GB2001/003702 WO2002016410A2 (en) | 2000-08-21 | 2001-08-17 | Peptide selection method |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0113400A true BR0113400A (pt) | 2003-07-08 |
Family
ID=26244875
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0113400-0A BRPI0113400B1 (pt) | 2000-08-21 | 2001-08-17 | Método para seleção de peptídeo |
BR0113400-0A BR0113400A (pt) | 2000-08-21 | 2001-08-17 | Método para seleção de peptìdeo |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0113400-0A BRPI0113400B1 (pt) | 2000-08-21 | 2001-08-17 | Método para seleção de peptídeo |
Country Status (25)
Country | Link |
---|---|
US (4) | US20030191063A1 (pt) |
EP (3) | EP1918298B1 (pt) |
JP (1) | JP5431628B2 (pt) |
KR (1) | KR20030062321A (pt) |
CN (4) | CN102784385B (pt) |
AT (2) | ATE483729T1 (pt) |
AU (2) | AU2001278637B2 (pt) |
BR (2) | BRPI0113400B1 (pt) |
CA (1) | CA2420949C (pt) |
CY (3) | CY1108558T1 (pt) |
CZ (1) | CZ307202B6 (pt) |
DE (2) | DE60134862D1 (pt) |
DK (3) | DK1918298T3 (pt) |
ES (3) | ES2310558T3 (pt) |
HK (3) | HK1052359B (pt) |
HU (3) | HU229489B1 (pt) |
IL (1) | IL154089A0 (pt) |
MX (1) | MXPA03001606A (pt) |
NO (2) | NO330535B1 (pt) |
NZ (1) | NZ523841A (pt) |
PH (1) | PH12013500208B1 (pt) |
PL (4) | PL215187B1 (pt) |
PT (3) | PT1311542E (pt) |
SI (3) | SI1311542T1 (pt) |
WO (1) | WO2002016410A2 (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0113400B1 (pt) | 2000-08-21 | 2018-05-15 | Apitope Technology Bristol | Método para seleção de peptídeo |
GB0202399D0 (en) | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
US20100003228A1 (en) * | 2006-05-05 | 2010-01-07 | Willimas Jim C | T-cell vaccine |
GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
US9340580B2 (en) | 2007-08-15 | 2016-05-17 | Circassia Limited | Peptide with multiple epitopes |
CN101848725B (zh) * | 2007-10-31 | 2013-05-22 | 艾匹托普技术(布里斯托尔)有限公司 | 组合物 |
GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
ITMI20080508A1 (it) * | 2008-03-27 | 2009-09-28 | Istituto Nazionale Di Genetica Molecolare | Cellule ematopoietiche esprimenti la proteina krtcap3 e i leganti per la proteina krtcap3 |
ITMI20080865A1 (it) * | 2008-05-13 | 2009-11-14 | Istituto Naz Di Genetica Molecolare Ingm | Cellule ematopoietiche esprimenti la proteina susd3 e i leganti per la proteina susd3 |
WO2010127186A1 (en) | 2009-04-30 | 2010-11-04 | Prognosys Biosciences, Inc. | Nucleic acid constructs and methods of use |
GB0908515D0 (en) | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
ES2566230T3 (es) | 2009-10-12 | 2016-04-11 | Lifebio Laboratories Llc | Composición para el tratamiento de la esclerosis múltiple |
RU2448685C2 (ru) * | 2009-11-30 | 2012-04-27 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза |
DK2556171T3 (en) | 2010-04-05 | 2015-12-14 | Prognosys Biosciences Inc | Spatially CODED BIOLOGICAL ASSAYS |
US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
KR200457779Y1 (ko) * | 2010-06-23 | 2012-01-06 | 이준혁 | 샤프펜슬 |
EP3150750B1 (en) | 2011-04-08 | 2018-12-26 | Prognosys Biosciences, Inc. | Peptide constructs and assay systems |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
PL397623A1 (pl) * | 2011-12-30 | 2013-07-08 | Napco S. Ar.L. | Preparat poprawiajacy pamiec oraz uczenie sie, sposób jego wytwarzania, srodek farmaceutyczny, dodatek zywieniowy oraz jego zastosowanie |
SG11201503657UA (en) | 2012-11-12 | 2015-06-29 | Apitope Int Nv | Peptides |
GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
EP2972366B1 (en) * | 2013-03-15 | 2020-06-17 | Prognosys Biosciences, Inc. | Methods for detecting peptide/mhc/tcr binding |
CN111662960B (zh) | 2013-06-25 | 2024-04-12 | 普罗格诺西斯生物科学公司 | 采用微流控装置的空间编码生物分析 |
GB201314052D0 (en) * | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
WO2015070037A2 (en) | 2013-11-08 | 2015-05-14 | Prognosys Biosciences, Inc. | Polynucleotide conjugates and methods for analyte detection |
KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
MX2017008505A (es) * | 2014-12-24 | 2018-03-07 | Apitope Int Nv | Composicion. |
DK3901281T3 (da) | 2015-04-10 | 2023-01-23 | Spatial Transcriptomics Ab | Rumligt adskilt, multipleks nukleinsyreanalyse af biologiske prøver |
EP3565585A1 (en) * | 2017-01-04 | 2019-11-13 | Apitope International NV | Therapeutic method using tolerogenic peptides |
GB201700095D0 (en) * | 2017-01-04 | 2017-02-22 | Apitope Int Nv | Composition |
JP7174492B2 (ja) * | 2017-01-04 | 2022-11-17 | ウォルグ ファーマシューティカルズ (ハンジョウ) カンパニー,リミテッド | S-アレスチンペプチドおよびその治療的使用 |
US10174122B2 (en) | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
GB201909774D0 (en) | 2019-07-08 | 2019-08-21 | Apitope Tech Bristol Limited | Method |
RU2761617C2 (ru) * | 2019-10-04 | 2021-12-13 | Жаудат Гафурович Умеров | Комплекс липидов миелина центральной и периферической нервной системы животных для лечения и профилактики нейродегенеративных демиелинизирующих нарушений и способы его применения |
GB201919222D0 (en) | 2019-12-23 | 2020-02-05 | Apitope Int Nv | Composition |
TR201922305A2 (tr) * | 2019-12-30 | 2021-07-26 | T C Erciyes Ueniversitesi | Multi̇pl skleroz (ms) hastaliğinda beta-kazomorfi̇n pepti̇tleri̇ni̇n kullanilmasi |
US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
US11702693B2 (en) | 2020-01-21 | 2023-07-18 | 10X Genomics, Inc. | Methods for printing cells and generating arrays of barcoded cells |
US11835462B2 (en) | 2020-02-11 | 2023-12-05 | 10X Genomics, Inc. | Methods and compositions for partitioning a biological sample |
US11926863B1 (en) | 2020-02-27 | 2024-03-12 | 10X Genomics, Inc. | Solid state single cell method for analyzing fixed biological cells |
WO2021144478A2 (en) | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
WO2021236929A1 (en) | 2020-05-22 | 2021-11-25 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1327162C (en) | 1987-04-09 | 1994-02-22 | Board Of Trustees Of The Leland Stanford Junior University (The) | Method for prophylactically treating an individual for an autoimmune disease |
EP0666080B1 (en) | 1987-06-24 | 2004-01-21 | Brigham & Women's Hospital | Treatment of autoimmune diseases by oral administration of autoantigens |
US5260422A (en) * | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
US5858980A (en) * | 1990-03-30 | 1999-01-12 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
IL165071A (en) * | 1990-03-30 | 2008-06-05 | Autoimmune Inc | A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients |
US5593698A (en) * | 1990-10-31 | 1997-01-14 | Autoimmune, Inc. | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
US5817629A (en) * | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US5989565A (en) * | 1993-01-29 | 1999-11-23 | University Of Pittsburgh | Elution and identification of T cell epitopes from viable cells |
CZ329596A3 (en) * | 1994-05-10 | 1997-05-14 | Immulogic Pharma Corp | Preparation for treating scattered sclerosis |
AU7242994A (en) | 1994-05-20 | 1995-12-18 | United States Of America, As Represented By The Secretary Of The Army, The | Model for testing immunogenicity of peptides |
US6379670B1 (en) * | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6251396B1 (en) * | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6329499B1 (en) * | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
EP0825870A4 (en) * | 1995-04-20 | 2002-09-25 | Brigham & Womens Hospital | MODULATION OF CYTOKINIC SEQUENCES OF SELF-REACTIVE T HUMAN CELL CLONES |
AU738649B2 (en) * | 1996-04-26 | 2001-09-20 | Rijksuniversiteit Te Leiden | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes |
EP0849275A1 (en) * | 1996-09-26 | 1998-06-24 | Rijksuniversiteit te Leiden | Mannosylated peptides |
EP1085892A4 (en) | 1998-06-12 | 2002-07-17 | Sloan Kettering Inst Cancer | VACCINE STRATEGY FOR THE PREVENTION AND TREATMENT OF CANCER |
MY129566A (en) * | 1999-01-19 | 2007-04-30 | Nestle Sa | A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance |
BRPI0113400B1 (pt) * | 2000-08-21 | 2018-05-15 | Apitope Technology Bristol | Método para seleção de peptídeo |
GB0202399D0 (en) | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
US8314290B2 (en) | 2004-12-21 | 2012-11-20 | Monsanto Technology Llc | Temporal regulation of gene expression by MicroRNAs |
CN101848725B (zh) | 2007-10-31 | 2013-05-22 | 艾匹托普技术(布里斯托尔)有限公司 | 组合物 |
GB0723712D0 (en) | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
-
2001
- 2001-08-17 BR BRPI0113400-0A patent/BRPI0113400B1/pt unknown
- 2001-08-17 HU HU0300814A patent/HU229489B1/hu not_active IP Right Cessation
- 2001-08-17 AT AT08002817T patent/ATE483729T1/de active
- 2001-08-17 CA CA2420949A patent/CA2420949C/en not_active Expired - Lifetime
- 2001-08-17 PT PT01956718T patent/PT1311542E/pt unknown
- 2001-08-17 PT PT08002817T patent/PT1918298E/pt unknown
- 2001-08-17 EP EP08002817A patent/EP1918298B1/en not_active Expired - Lifetime
- 2001-08-17 IL IL15408901A patent/IL154089A0/xx unknown
- 2001-08-17 PL PL399137A patent/PL215187B1/pl unknown
- 2001-08-17 JP JP2002521505A patent/JP5431628B2/ja not_active Expired - Fee Related
- 2001-08-17 AU AU2001278637A patent/AU2001278637B2/en not_active Ceased
- 2001-08-17 DE DE60134862T patent/DE60134862D1/de not_active Expired - Lifetime
- 2001-08-17 CN CN201210156674.1A patent/CN102784385B/zh not_active Expired - Fee Related
- 2001-08-17 HU HU1300358A patent/HU230233B1/hu not_active IP Right Cessation
- 2001-08-17 PL PL364048A patent/PL217929B1/pl unknown
- 2001-08-17 KR KR10-2003-7002514A patent/KR20030062321A/ko not_active Application Discontinuation
- 2001-08-17 CN CN201210156712.3A patent/CN102764425B/zh not_active Expired - Fee Related
- 2001-08-17 CN CN2009101296721A patent/CN101633689B/zh not_active Expired - Fee Related
- 2001-08-17 CZ CZ2003-512A patent/CZ307202B6/cs not_active IP Right Cessation
- 2001-08-17 NZ NZ523841A patent/NZ523841A/en not_active IP Right Cessation
- 2001-08-17 DE DE60143234T patent/DE60143234D1/de not_active Expired - Lifetime
- 2001-08-17 HU HU1300357A patent/HU229377B1/hu not_active IP Right Cessation
- 2001-08-17 SI SI200130860T patent/SI1311542T1/sl unknown
- 2001-08-17 PT PT60149010T patent/PT1731912E/pt unknown
- 2001-08-17 MX MXPA03001606A patent/MXPA03001606A/es active IP Right Grant
- 2001-08-17 DK DK08002817.8T patent/DK1918298T3/da active
- 2001-08-17 CN CNA018176828A patent/CN1469883A/zh active Pending
- 2001-08-17 ES ES01956718T patent/ES2310558T3/es not_active Expired - Lifetime
- 2001-08-17 DK DK06014901.0T patent/DK1731912T3/da active
- 2001-08-17 BR BR0113400-0A patent/BR0113400A/pt not_active IP Right Cessation
- 2001-08-17 PL PL399138A patent/PL215145B1/pl unknown
- 2001-08-17 WO PCT/GB2001/003702 patent/WO2002016410A2/en active Application Filing
- 2001-08-17 EP EP06014901.0A patent/EP1731912B1/en not_active Expired - Lifetime
- 2001-08-17 AU AU7863701A patent/AU7863701A/xx active Pending
- 2001-08-17 EP EP01956718A patent/EP1311542B1/en not_active Expired - Lifetime
- 2001-08-17 SI SI200131032T patent/SI1731912T1/sl unknown
- 2001-08-17 ES ES08002817T patent/ES2353347T3/es not_active Expired - Lifetime
- 2001-08-17 US US10/362,264 patent/US20030191063A1/en not_active Abandoned
- 2001-08-17 SI SI200130983T patent/SI1918298T1/sl unknown
- 2001-08-17 DK DK01956718T patent/DK1311542T3/da active
- 2001-08-17 PL PL395781A patent/PL213585B1/pl unknown
- 2001-08-17 ES ES06014901.0T patent/ES2439899T3/es not_active Expired - Lifetime
- 2001-08-17 AT AT01956718T patent/ATE401343T1/de active
-
2003
- 2003-02-19 NO NO20030790A patent/NO330535B1/no not_active IP Right Cessation
- 2003-06-26 HK HK03104592.1A patent/HK1052359B/zh not_active IP Right Cessation
-
2007
- 2007-10-31 US US11/979,224 patent/US8343500B2/en not_active Expired - Fee Related
-
2008
- 2008-10-13 CY CY20081101132T patent/CY1108558T1/el unknown
-
2010
- 2010-10-18 NO NO20101441A patent/NO337988B1/no not_active IP Right Cessation
-
2011
- 2011-01-04 CY CY20111100017T patent/CY1111079T1/el unknown
-
2012
- 2012-12-06 US US13/706,540 patent/US8961986B2/en not_active Expired - Fee Related
-
2013
- 2013-01-31 PH PH12013500208A patent/PH12013500208B1/en unknown
- 2013-05-03 HK HK13105346.5A patent/HK1178437A1/xx not_active IP Right Cessation
- 2013-05-16 HK HK13105845.1A patent/HK1178793A1/xx not_active IP Right Cessation
- 2013-12-18 CY CY20131101143T patent/CY1114808T1/el unknown
-
2018
- 2018-03-20 US US15/926,637 patent/US20180311328A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113400A (pt) | Método para seleção de peptìdeo | |
BR0111196A (pt) | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus | |
BR0115427A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto | |
BR9807577A (pt) | Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição | |
BR9913323A (pt) | Processo para vacinar um mamìfero contra umestado doentio, composição de vacina, uso de umcomposto, e, combinação de componentes paraadministração separada, sequencial ouconcomitante no processo | |
BR9708632A (pt) | Composto calcilìticos | |
BR0201719A (pt) | Composições farmacêuticas agradáveis ao paladar para animais de companhia | |
BR0212374A (pt) | Oxintomodulina para a prevenção ou para o tratamento do excesso de peso | |
BR0111127A (pt) | Métodos e composições para tratamento do vìrus de hepatite c | |
BRPI0519195A2 (pt) | composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal | |
PT777482E (pt) | Composicao de combinacao para utilizacao em doencas imunologicas | |
TR200101481T2 (tr) | Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi. | |
EA200000994A1 (ru) | Применение кабэрголина при лечении синдрома усталых ног | |
BR9914901A (pt) | Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca | |
ATE83663T1 (de) | Imipramin enthaltende arzneizubereitungen. | |
BR9809951A (pt) | Método para tratamento da obesidade | |
BR9914631A (pt) | Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades | |
BR0312768A (pt) | Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos | |
BR0009524A (pt) | Uso de um composto, e, composição farmacêutica ou veterinaria | |
SE9801495D0 (sv) | Protein formulationa | |
BR0115518A (pt) | Kit de repinotan | |
BR0207827A (pt) | Método de preparação de uma micropartìcula homogênea que compreende um inibidor de h+/k+-atpase ácido lábil, micropartìcula, composição farmacêutica, método para prevenir ou tratar uma doença relacionada com o ácido gástrico em um mamìfero, e, uso de uma micropartìcula | |
BR0201524A (pt) | Tratamento de combinação para ansiedade e depressão | |
BR0213181A (pt) | Combinações de inibidor de cox-2 | |
BR0115424A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |